Ogawa Kazuhiko, Shikama Naoto, Toita Takafumi, Nakamura Katsumasa, Uno Takashi, Onishi Hiroshi, Itami Jun, Kakinohana Yasumasa, Kinjo Takao, Yoshii Yoshihiko, Ito Hisao, Murayama Sadayuki
Department of Radiology, University of the Ryukyus, Okinawa, Japan.
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):705-13. doi: 10.1016/j.ijrobp.2003.07.001.
Optimal management of radiotherapy (RT) for intracranial germinoma remains controversial. This study was conducted to evaluate the long-term results of RT in patients with these tumors.
The study group consisted of 126 patients with intracranial germinoma (50 patients with pathologically verified germinoma and 76 clinically diagnosed with germinoma by clinical and neuroradiologic signs) who were treated by RT alone between 1980 and 2001. The median age at diagnosis was 17 years (range, 2-47), and various radiation doses and treatment fields were used. Serum human chorionic gonadotropin (hCG) levels were elevated in 18 patients. The median follow-up of the 114 surviving patients was 122 months (range, 13-263).
The 10-year actuarial overall survival and cause-specific survival rate for all patients was 90% and 95%, respectively. The 10-year actuarial cause-specific survival rate for patients with and without elevated hCG levels was 94%. Relapses were noted in 10 patients, 7 of whom died of the disease. No in-field relapses at primary sites were observed in 72 patients treated with total doses of 40-50 Gy. The incidence of spinal relapses was 4% (2 of 56) for patients treated with spinal irradiation and 3% (2 of 70) for those without spinal irradiation. After a median 10-year follow-up, 54 (92%) of 59 patients with tumors not involving the neurohypophyseal region and 42 (76%) of 55 patients with tumors involving the neurohypophyseal region had Karnofsky performance status scores of 90-100%. With regard to school education and occupation, 54 (92%) of 59 patients with tumors not involving the neurohypophyseal region and 39 (71%) of 55 patients with tumors involving the neurohypophyseal region were attending school or undertaking occupations. Hormonal replacement therapy was required in 50 (44%) of 114 surviving patients before RT; only 4 patients (4%), all with neurohypophyseal tumors, required hormonal replacement therapy after RT. Clinically evident severe neurocognitive dysfunctions were documented in 10 patients before RT, and no patients treated with total doses of <55 Gy developed apparent neurocognitive dysfunctions or other complications after RT.
RT was a curative treatment for intracranial germinoma, and elevated serum hCG levels did not affect the prognosis of patients treated by RT alone. A total dose of 40-50 Gy to adequate treatment fields was effective in preventing intracranial relapse, and the incidence of spinal relapses was too low to warrant routine spinal irradiation. Karnofsky performance status scores, educational achievement, and the ability to work were generally good, particularly in patients with tumors that did not involve the neurohypophyseal region. Because most complications, such as hormonal deficiency and neurocognitive dysfunction, were documented before RT and newly diagnosed complications after RT were infrequent, the treatment toxicity faced by germinoma patients appears to be less than anticipated.
颅内生殖细胞瘤放疗(RT)的最佳管理仍存在争议。本研究旨在评估这些肿瘤患者放疗的长期结果。
研究组由1980年至2001年间仅接受放疗的126例颅内生殖细胞瘤患者组成(50例经病理证实为生殖细胞瘤,76例根据临床和神经放射学征象临床诊断为生殖细胞瘤)。诊断时的中位年龄为17岁(范围2 - 47岁),采用了不同的放射剂量和治疗野。18例患者血清人绒毛膜促性腺激素(hCG)水平升高。114例存活患者的中位随访时间为122个月(范围13 - 263个月)。
所有患者的10年精算总生存率和病因特异性生存率分别为90%和95%。hCG水平升高和未升高的患者10年精算病因特异性生存率均为94%。10例患者出现复发,其中7例死于该疾病。接受40 - 50 Gy总剂量治疗的72例患者在原发部位未观察到野内复发。接受脊髓照射的患者脊髓复发率为4%(56例中的2例),未接受脊髓照射的患者为3%(70例中的2例)。中位随访10年后,59例肿瘤未累及神经垂体区域的患者中有54例(92%)、55例肿瘤累及神经垂体区域的患者中有42例(76%)卡氏功能状态评分为90 - 100%。在学校教育和职业方面,59例肿瘤未累及神经垂体区域的患者中有54例(92%)、55例肿瘤累及神经垂体区域的患者中有39例(71%)正在上学或从事职业。114例存活患者中有50例(44%)在放疗前需要激素替代治疗;放疗后仅4例患者(4%)需要激素替代治疗,且均为神经垂体肿瘤患者。放疗前有10例患者记录有临床明显的严重神经认知功能障碍,接受总剂量<55 Gy治疗的患者放疗后未出现明显的神经认知功能障碍或其他并发症。
放疗是颅内生殖细胞瘤的一种治愈性治疗方法,血清hCG水平升高不影响单纯放疗患者的预后。给予足够治疗野40 - 50 Gy的总剂量可有效预防颅内复发,但脊髓复发率过低,无需常规进行脊髓照射。卡氏功能状态评分、教育成就和工作能力总体良好,尤其是肿瘤未累及神经垂体区域的患者。由于大多数并发症,如激素缺乏和神经认知功能障碍,在放疗前已有记录,放疗后新诊断的并发症很少见,因此生殖细胞瘤患者面临的治疗毒性似乎比预期的要小。